Evoke Pharma
EVOK
#9899
Rank
$6.43 M
Marketcap
$4.33
Share price
-5.04%
Change (1 day)
-71.13%
Change (1 year)

P/E ratio for Evoke Pharma (EVOK)

P/E ratio as of November 2024 (TTM): -1.83

According to Evoke Pharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.83475. At the end of 2022 the company had a P/E ratio of -12.2.

P/E ratio history for Evoke Pharma from 2013 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-12.2-51.55%
2021-25.1-57.77%
2020-59.51.07%
2019-58.9-8.94%
2018-64.7100.38%
2017-32.369.15%
2016-19.1-8.9%
2015-21.0-35.19%
2014-32.3-52.08%
2013-67.5

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-0.5840-68.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-121 6,499.54%๐Ÿ‡บ๐Ÿ‡ธ USA
21.6-1,279.87%๐Ÿ‡บ๐Ÿ‡ธ USA
-20.3 1,008.23%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.